APA-viite

Xin, P., Li, C., Zheng, Y., Peng, Q., Xiao, H., Huang, Y., & Zhu, X. (2017). Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Drug Des Devel Ther.

Chicago-tyylinen lähdeviittaus

Xin, Pengliang, Chuntuan Li, Yan Zheng, Qunyi Peng, Huifang Xiao, Yuanling Huang, ja Xiongpeng Zhu. "Efficacy of the Dual PI3K and MTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate against Chronic Myelogenous Leukemia Cell Lines." Drug Des Devel Ther 2017.

MLA-viite

Xin, Pengliang, et al. "Efficacy of the Dual PI3K and MTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate against Chronic Myelogenous Leukemia Cell Lines." Drug Des Devel Ther 2017.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.